SUMMARY
Federal rescheduling, from Schedule I to III is a watershed moment. President Trump’s December 2025 executive order to move cannabis from Schedule I to Schedule III portends to be the most consequential federal cannabis action to date. It aligns federal policy more closely with 40 state medical programs and unlocks research, investment, and regulatory clarity that has been blocked for decades. Cannabis reform is broadly consistent with the Trump agenda, and incremental regulatory developments over recent years point to a low probability of the policy remaining unchanged.
Immediate economic impact: taxes, investment, and growth. As new state markets continue to open, public support remains overwhelming, and the economic benefits become increasingly evident, the issue has undoubtedly gained relevance at the federal level. Schedule III eliminates the punitive 280E tax rule (cannabis companies are currently taxed on gross profit), materially improving cash flow, access to capital, and valuations. Rescheduling broadens the lender and investor universe (banks, institutional funds, pharma, private equity, public markets), accelerates job creation, small business growth, and tax revenue. Legal U.S. cannabis sales are estimated at a whopping ~$32B in 2025, with much larger pharmaceutical and wellness market opportunities ahead.
Medical cannabis is being “recalibrated” into mainstream medicine. Reduced research barriers will drive clinical trials into FDA-approved drugs, standardized dosing, and physician adoption. Cannabis-based therapeutics target massive unmet markets (pain, inflammation, sleep, neurological diseases). Increased demand expected as large pharmaceutical firms contend with a growing wave of patent expirations in the coming years (estimated in the hundreds of billions of US$). Precedents like Epidiolex and the $7.2B GW Pharma acquisition by Jazz Pharmaceuticals validate the pharmaceutical potential.
Hemp-CBD and intoxicating hemp products face a regulatory reset. Farm Bill loopholes allowed unregulated, psychoactive hemp products into the market (delta-8, delta-10), creating public safety issues and market chaos. Anticipated legislative reform and potential cannabis rescheduling are expected to close these loopholes, favoring compliant operators and restoring stability across the CBD market, including CBD for pet dogs and cats(a large, untapped market). A Medicare CBD pilot (up to $500/year for seniors) creates a potential ~$30B TAM if clarified and implemented cleanly. Glass House Brands (OTCMKTS: GLASF) in particular, is strategically positioned to benefit from these developments.
Rescheduling is a prelude—not the endgame. Schedule III sets the stage for federal standardization, improved banking access, enforcement clarity, and eventual de-scheduling/legalization. National testing, quality, and labeling standards are likely to materialize before full legalization. Industry normalization (enabling up-listing to major stock exchanges, capital market flows, talent, stigma reduction) is expected to follow, accelerating long-term growth.